Dexamethasone and Lugua peptide in osteoblast proliferation and differentiation: inhibitive or promotive effects?

doi:10.3969/j.issn.2095-4344.2014.15.004

Abstract

Abstract:

BACKGROUND: The incidence of osteoporosis caused by long-term use of dexamethasone injection is increasing, but there is no exact treatment. Lugua peptide injection is a common drug to promote fracture healing and increase bone density.
OBJECTIVE: To observe the effect of Lugua peptide injection plus high-concentration dexamethasone on osteoblast proliferation and differentiation.
METHODS: The rat osteoblasts were randomly divided into three groups. Lugua peptide plus dexamethasone group was injected with 1×10^-7 mol/L dexamethasone, 8 mg/L Lugua peptide and dimethyl sulfoxide (final concentration 1 g/L). Dexamethasone group was injected with 1×10^-7 mol/L dexamethasone and dimethyl sulfoxide (final concentration 1 g/L). Control group was injected with dimethyl sulfoxide (final concentration 1 g/L). After 96 hours, the expression of osteocalcin was analyzed by RT-PCR analysis; at 21 days, the expression of calcium nodules was observed by alizarin red staining.
RESULTS AND CONCLUSION: The osteocalcin mRNA expression and calcium nodule expression in Lugua peptide plus dexamethasone group and control group were higher than that in dexamethasone group (P < 0.01), while there was no significant difference between Lugua peptide plus dexamethasone group and control group (P > 0.05). Lugua peptide injection can prevent the inhibitory effect of high concentrations of dexamethasone on the osteoblast proliferation and differentiation.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: dexamethasone, glucocorticoids, osteoblasts, osteoporosis, osteocalcin

CLC Number:

R318

Duan Feng, Wen Ke-han, Wang Xin-yu, Zhang Guo-liang, Dai Xin-peng, Guo Huan-huan . Dexamethasone and Lugua peptide in osteoblast proliferation and differentiation: inhibitive or promotive effects? [J]. Chinese Journal of Tissue Engineering Research, 2014, 18(15): 2314-2319.

Figures/Tables 4

References

[1]Seeman E, Delmas PD. Bone qualitydthe material and structural basis of bone strength and fragility. Engl J Med. 2006;354:22.50-61.
[2]Zhou XW,Liu YC,Jian XC. Effects of osteoporosis on oral and maxillofacial bone. Chin J Clin Rehabil. 2005;9(11):248-249.
[3]Him T, Ishijima T,Hashikawa Y,et al.Osteoporosis and reduction of residual ridage in edentulous patients.J Prosthet Dent. 1993;69(1):49-56.
[4]Derbis E.Oralimplications of osteoporosis.Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100(3):349-356.
[5]Rodan,GA, Martion TJ. Therap eutic approaches to bone diseases. Science. 2000;289(5484):1508-1514.
[6]Chen XD,Shi S,Xu T,et al.Age-related osteoporosis in biglycan deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res. 2002;17(2):331-340.
[7]Miura M,Chen XD,Allen MR,et al.A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells. J Clin Invest. 2004;114(12):1704-1713.
[8]Ishida Y,Heersehe JN. Glueoeortieoidinduced osteoPorosis:both in vivoandinvitro Eoncentrations of glueoeortieoids higher than Physiological levels attenuate osteoblast Differentiation .J Bone Miner Res. 1998 ;13(12): 1822-1861.
[9]Vaanaen KH,Hakonen PL.Bone effeets of glucocorticoid therapy. Emst Sehering Res Found Workshop. 2002;(40): 55-64.
[10]Chen YJ, Tracey J, Nickola, et al. Dexamethasone-Mediated Repression of MUC5AC Gene Expression in Human Lung Epithelial Cells. Cell Mol Biol. 2006;34(3): 338-347.
[11]陆茂,叶俊儒,张云光,等. 鹿瓜多肽注射液治疗糖皮质激素性骨质疏松症的疗效观察[J].当代医学,2008,15(8):145-147.
[12]赵正旭,郝毅,茹选良．鹿瓜多肽注射液治疗原发性骨质疏松症疗效观察[J].中国骨与关节损伤杂志,2006,6(11):500-501．
[13]高晓新,翟文生,王和枚,等. 大鼠腹腔注射鹿瓜多肽重复给药13周毒性病理评价[J].中国药理学与毒理学杂志,2013,6(3): 530-531.
[14]林文鑫．鹿瓜多肽的药理作用和临床应用[J]．实用全科医学杂志,2006,4(6):730-733.
[15]章静波, 张世馥, 黄东阳. 组织和细胞培养技术[M].北京:人民卫生出版社, 2002:96-98.
[16]Kern B, Shen J, Starbuck M, et al. Cbfa1 contributes to the osteoblastspecifi cexpression of type I collagen genes. J Biol Chem. 2001;276(10):7101-7107.
[17]Janknecht R. Regulation of the c-fos promoter. Immunobiology. 1995;193(2-4):137-142.
[18]Wagner EF. Functions of AP1 (Fos/Jun) in bone development. AnnRheum Dis. 2002;61:ii40-22.
[19]Hauschka PV. Osteocalcin: the vitamin K-dependent Ca2+- binding protein of bone matrix. Haemostasis. 1986;16(3-4): 258-272.
[20]Nojima N, Kobayashi M, Shionome M, et al. Fibroblastic cells derived from bovine periodontal ligaments have the phenotypes of osteoblasts. Periodontal Res.1990; 25(3): 179-185.
[21]徐西强,李峰,李昆鹏,等.鹿瓜多肽注射液对大鼠成骨细胞增殖及分化影响[J]. 中国中医骨伤科杂志,2011, 19( 9):6-9.
[22]王丽红,何英,徐永柱. 鹿瓜多肽联合 hBMP-2 基因对软骨细胞增殖和Ⅱ型胶原分泌的影响[J].中国老年学杂志,2011,5(31): 1577-1580.
[23]扬林,陶天遵,刘枫晨,等.地塞米松对成人成骨细胞增殖和分化影响的实验研究[J]中华骨科杂志, 2001, 21(8): 493.
[24]周先培,倪江东. 不同浓度地塞米松对大鼠干细胞体外诱导分化成骨细胞的影响[D].中南大学，2005.
[25]Weinstein RS, Jilka RL,Parfitt AM, et a.l Inhibition of osteoblastogenesis and promotion of apoptosis ofosteoblasts and osteocytes by glucocorticoids. Potentialmechanisms of theirdeleterious effects on bone. Clin Invest. 2008;102(2):274.
[26]郭世绂,罗先正,邱贵兴.骨质疏松基础与临床[M].天津:天津科学技术出版社, 2001: 384.
[27]Qu Q, Perala-Heape M, Kapanen A,et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone. 1998;22(3):201-209.
[28]Owen TA, Aronow M, Shalhoub V, et al. Progressive development of the rat osteoblast phenotype in vitro:reciprocal relationships in expression of genes associated with osteoblast proliferation and differentiation during formation of the bone extracellular matrix. J Cell Physiol. 2010;143(3):420-430.
[29]Majors AK, Boehm CA, Nitto H, et al. Characterization of human bone marrow stromal cells with respect to osteoblastic differentiation. J Orthop Res. 1997;15(4):546-557.
[30]Stanford CM, Jacobson PA, Eanes ED, et al. Rapidly forming apatitic mineral in an osteoblastic cell line (UMR 106-01 BSP). J.Biol Chem. 1995;270(16):420-456.
[31]贺茂林,肖增明. 糖皮质激素性骨质疏松症的研究进展[J]. 中国骨质疏松杂志,2009,15(6):466-470.
[32]李春香,刘红,徐艳,等. 唑来膦酸治疗糖皮质激素性骨质疏松症的临床观察[J].中国骨质疏松杂志,2013,19(12):1262-1264.
[33]孔德诚,王莉,白人骁,等.糖皮质激素引起骨质疏松的发病机制及其防治措施[J].中国骨质疏松杂志,1999,5(3):70-72
[34]王剑,郑洪新,刘研,等. 补肾益髓中药复方对糖皮质激素性骨质疏松症大鼠肾组织Osterix mRNA及蛋白表达的影响[J].光明中医,2012,27(4):673-677.
[35]王剑,郑洪新,刘瑞辉,等. 补肾中药复方对糖皮质激素性骨质疏松症大鼠骨和肾组织Dlx5 mRNA及蛋白表达的影响[J].中华中医药杂志,2012,23(4):951-856.
[36]何淼泉,徐莉,范永升. 中医药调控糖皮质激素性骨质疏松症机制研究[J].浙江中西医结合杂志,2012,22(4):329-331
[37]黄春雷,吴斌. 吸入糖皮质激素治疗支气管哮喘与骨质疏松的研究进展[J]. 国际呼吸杂志,2011,31(15):1190-1194.
[38]张国哲,郑洪新,朱辉,等. 补肾中药对糖皮质激素性骨质疏松大鼠脂类代谢异常的调节作用[J].辽宁中医药大学学报,2011, 13(6): 53-56.
[39]李洪涛,于雪峰,李登宇,等. 糖皮质激素性骨质疏松症发病机理研究进展[J]. 中国骨质疏松杂志,2009,15(2):150-152.
[40]徐晓东,邓洋洋,郑洪新. 糖皮质激素诱导肾虚骨质疏松症大鼠骨组织中OPG/RANKLmRAN及蛋白表达的影响[J]. 中华中医药学刊,2013,32(12):2623-2627.